ATE460175T1 - Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung - Google Patents

Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung

Info

Publication number
ATE460175T1
ATE460175T1 AT00981127T AT00981127T ATE460175T1 AT E460175 T1 ATE460175 T1 AT E460175T1 AT 00981127 T AT00981127 T AT 00981127T AT 00981127 T AT00981127 T AT 00981127T AT E460175 T1 ATE460175 T1 AT E460175T1
Authority
AT
Austria
Prior art keywords
preparation
interferon
aqueous formulation
stable aqueous
interferon alpha
Prior art date
Application number
AT00981127T
Other languages
English (en)
Inventor
Lei Zhang
Original Assignee
Tianjin Hualida Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hualida Biotechnology filed Critical Tianjin Hualida Biotechnology
Application granted granted Critical
Publication of ATE460175T1 publication Critical patent/ATE460175T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00981127T 1999-12-06 2000-12-05 Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung ATE460175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB991255828A CN1175901C (zh) 1999-12-06 1999-12-06 一种稳定的干扰素水溶液
PCT/CN2000/000531 WO2001041793A1 (fr) 1999-12-06 2000-12-05 Formulation stable d'interferon en solution, son procede de preparation et ses applications

Publications (1)

Publication Number Publication Date
ATE460175T1 true ATE460175T1 (de) 2010-03-15

Family

ID=5284022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981127T ATE460175T1 (de) 1999-12-06 2000-12-05 Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung

Country Status (10)

Country Link
US (1) US20030170207A1 (de)
EP (1) EP1250932B1 (de)
CN (1) CN1175901C (de)
AT (1) ATE460175T1 (de)
AU (1) AU1848901A (de)
BR (1) BR0016304A (de)
DE (1) DE60043994D1 (de)
MX (1) MXPA02005563A (de)
RU (1) RU2242242C2 (de)
WO (1) WO2001041793A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
EP1750751B1 (de) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilisierte flüssige interferon-formulierungen
CN1724567B (zh) * 2004-07-22 2010-08-18 北京三元基因工程有限公司 一种稳定的重组人干扰素α1b水溶液
RU2255729C1 (ru) * 2004-07-26 2005-07-10 Общество С Ограниченной Ответственностью "Фармапарк" Препарат интерферона альфа в форме стабильного водного раствора для инъекций
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
RU2319502C1 (ru) * 2006-11-08 2008-03-20 Общество С Ограниченной Ответственностью "Фармапарк" РАСТВОР ДЛЯ ИНЪЕКЦИЙ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pSX50, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО АЛЬФА-2b ИНТЕРФЕРОНА, ШТАММ Escherichia coli SX50 - ПРОМЫШЛЕННЫЙ ШТАММ-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО АЛЬФА-2b ИНТЕРФЕРОНА И СПОСОБ ПРОМЫШЛЕННОГО ПОЛУЧЕНИЯ ИНТЕРФЕРОНА АЛЬФА-2b
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102988984B (zh) * 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
RU2564951C1 (ru) * 2014-08-28 2015-10-10 Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") Композиция водного раствора рекомбинантного интерферона альфа-2 человека для ректального применения
CN106421755A (zh) * 2016-11-03 2017-02-22 广州凯耀资产管理有限公司 一种干扰素组合物及其制备方法
EP3970803A1 (de) * 2020-09-22 2022-03-23 Beiersdorf AG Kosmetische zusammensetzung mit geringer osmolalität
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用
CN115177719A (zh) * 2022-07-29 2022-10-14 广州源博医药科技有限公司 一种犬α干扰素水针剂型及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (de) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stabile Gamma-Interferon-Zusammensetzung
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6261800B1 (en) * 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution

Also Published As

Publication number Publication date
CN1175901C (zh) 2004-11-17
RU2002118115A (ru) 2004-02-20
AU1848901A (en) 2001-06-18
US20030170207A1 (en) 2003-09-11
MXPA02005563A (es) 2004-09-10
CN1256148A (zh) 2000-06-14
EP1250932B1 (de) 2010-03-10
BR0016304A (pt) 2002-11-05
DE60043994D1 (de) 2010-04-22
EP1250932A4 (de) 2006-04-19
WO2001041793A1 (fr) 2001-06-14
EP1250932A1 (de) 2002-10-23
RU2242242C2 (ru) 2004-12-20

Similar Documents

Publication Publication Date Title
ATE460175T1 (de) Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung
IS4100A (is) Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
ATE76569T1 (de) Konservierte haar- und koerperreinigungsmittel sowie verwendung einer konservierungsstoffkombination.
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
DK1343472T3 (da) Thixotropisk næsespray
DK1146906T3 (da) Mukosalt afgivelsessystem
DK0783307T3 (da) Anvendelse af 2,4-diaminopyrimidin-3-oxid eller et salt deraf til behandling af forstyrrelser i modning og strukturering af kollagen
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
ATE205399T1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
DE60045638D1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE61522T1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
BR0208554A (pt) Osteoprotegerina no leite
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
DK93091D0 (da) Laegemidler til behandling af toxoplasmose
NZ235297A (en) Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution
DE60122680D1 (de) Kannulationsanordnung
HRP20030701A2 (en) Natural antibodies active against hiv virus
DE60111493D1 (de) Campher wässrige lösung zur behandlung degenerativer und autoimmuner erkrankungen sowie als immunomodulator

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties